Zhejiang Dayang Biotech Group Co Ltd

Chart & Performance

D1W1MN

P/E

31.63

P/S

1.72

EPS

0.61

Div Yield, %

2.69%

Shrs. gr., 5y

14.02%

Rev. gr., 5y

9.50%

Revenues

919m

-13.10%

Net income

50m

-38.05%

CFO

182m

+98.53%

Dividend

Jul 11, 20240.45 CNY/sh

Earnings

May 21, 2025

Profile

Zhejiang Dayang Biology Technology Co.,Ltd. engages in research and development, production, and sale of biological products, agricultural chemicals, and chemical in China and internationally. The company's products include food additive potassium carbonate, potassium carbonate, food additive potassium bicarbonate, potassium bicarbonate, agricultural grade ammonium chloride, and industrial grade ammonium chloride. It also offers chemical products, such as 2-chloro-6-fiuorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and anisole products; veterinary APIs, including amprolium HCL; and veterinary drug premixes comprising enramycin premixes. The company was founded in 1976 and is based in Jiande, China.

URL

http://www.dyhg.com/

IPO date

Oct 26, 2020

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2016‑00	2015‑00
Income
Revenues	919,451 -13.10%	1,058,105 35.10%	783,209 15.46%
Cost of revenue	867,494	968,288	682,567
Unusual Expense (Income)
NOPBT	51,958	89,817	100,642
NOPBT Margin	5.65%	8.49%	12.85%
Operating Taxes	(3,020)		6,129
Tax Rate			6.09%
NOPAT	54,978	89,817	94,513
Net income	50,007 -38.05%	80,727 15.31%	70,009 -23.58%
Dividends	(42,607)	(34,320)	(36,000)
Dividend yield	2.17%	1.52%	1.03%
Proceeds from repurchase of equity		(1)
BB yield		0.00%
Debt
Debt current	180,435	282,143	139,071
Long-term debt	69,934		41,535
Deferred revenue	11,353	11,961	9,596
Other long-term liabilities	1	1	1
Net debt	(186,838)	(145,446)	(231,042)
Cash flow
Cash from operating activities	182,423	91,887
CAPEX	(103,627)
Cash from investing activities	145,084		8,891
Cash from financing activities	(75,675)	16,871	89,396
FCF	68,281	50,152	(9,559)
Balance
Cash	382,366	427,589	411,648
Long term investments	54,840
Excess cash	391,234	374,684	372,488
Stockholders' equity	521,719	492,212	426,718
Invested Capital	877,822	889,469	803,380
ROIC	6.22%	10.61%	12.53%
ROCE	4.01%	6.93%	8.44%
EV
Common stock shares outstanding	80,734	81,542	84,000
Price	24.32 -12.23%	27.71 -33.71%	41.80 -19.23%
Market cap	1,963,453 -13.10%	2,259,539 -35.65%	3,511,200 -19.23%
EV	1,776,616	2,114,093	3,280,158
EBITDA	121,632	150,067	145,741
EV/EBITDA	14.61	14.09	22.51
Interest	6,680	5,478	3,721
Interest/NOPBT	12.86%	6.10%	3.70%